Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic merkel cell carcinoma (mMCC) progressed on chemotherapy

Tom van Hagen; Shahneen Sandhu; Paul Nghiem; Shailender Bhatia; Andrew S. Brohl; Omid Hamid; Janice M. Mehnert; Patrick Terheyden; Kent C. Shih; Isaac Brownell; Célèste Lebbé; Karl D. Lewis; Gerald P. Linette; Michèle Milella; Meliessa Hennessy; Marcis Bajars; Christine Hicking; Sandra P. D’Angelo

Article2018

Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic merkel cell carcinoma (mMCC) progressed on chemotherapy

Tom van Hagen, Shahneen Sandhu, Paul Nghiem, Shailender Bhatia, Andrew S. Brohl, Omid Hamid, Janice M. Mehnert, Patrick Terheyden, Kent C. Shih, Isaac Brownell, Célèste Lebbé, Karl D. Lewis, Gerald P. Linette, Michèle Milella, Meliessa Hennessy, Marcis Bajars, Christine Hicking, Sandra P. D’Angelo

Article2020

Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program

John Walker, Célèste Lebbé, Giovanni Grignani, Paul Nathan, Luc Dirix, Eyal Fenig, Paolo A. Ascierto, Shahneen Sandhu, Rodrigo Ramella Munhoz, Elena Benincasa, Sarah Flaskett, Josh Reed, Arne Engelsberg, Hariharan Subramanian, Vijay Kasturi

Article2019

Avelumab treatment of metastatic merkel cell carcinoma (mMCC): Updated findings from Australian patients enrolled in an expanded access program(EAP)

Shahneen Sandhu, Vijay Kasturi, Alex Guminski, Christopher Steer, Victoria Atkinson, Ina Nordman, Peter L. Tobin, Josh Reed, Nuno Costa

Article2018

Second-line avelumab treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from a global expanded access program (EAP).

John Walker, Vijay Kasturi, Célèste Lebbé, Shahneen Sandhu, Giovanni Grignani, Meliessa Hennessy, Steven Hildemann, Josh Reed, Hariharan Subramanian

Article2021

Durability of response to immune checkpoint inhibitors (ICI) in metastatic Merkel cell carcinoma (mMCC) after treatment cessation.

Georgina V. Long, Ina Nordman, Christopher Steer, Megan Lyle, Claudia Trojaniello, Paolo A. Ascierto, Célèste Lebbé, Shahneen Sandhu, Alison M. Weppler, Laetitia Da Meda, Inês Pires da Silva, Wen Xu, Giovanni Grignani, Alexander M. Menzies, Matteo S. Carlino

Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic merkel cell carcinoma (mMCC) progressed on chemotherapy

Discussion(0)

Related publications

Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic merkel cell carcinoma (mMCC) progressed on chemotherapy

Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program

Avelumab treatment of metastatic merkel cell carcinoma (mMCC): Updated findings from Australian patients enrolled in an expanded access program(EAP)

Second-line avelumab treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from a global expanded access program (EAP).

Durability of response to immune checkpoint inhibitors (ICI) in metastatic Merkel cell carcinoma (mMCC) after treatment cessation.